FDA Clearance Tracker · P040020-S087
AcrySof IQ PanOptix Trifocal Intraocular Lens and AcrySof IQ PanOptix Toric Trifocal Intraocular Lens
Last checked: Nov 20, 2026Latest source record: Aug 26, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Aug 26, 2019
Approved
Time to decision
207 days
Received Jan 31, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P040020-S087
- Device name
- AcrySof IQ PanOptix Trifocal Intraocular Lens and AcrySof IQ PanOptix Toric Trifocal Intraocular Lens
- Applicant
- Alcon Research, Ltd.
- Applicant location
- Fort Worth, TX
- Received
- Jan 31, 2019
- Decided
- Aug 26, 2019
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P040020
Device type
- Device type
- Lens, multifocal intraocular (MFK)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the AcrySof® IQ PanOptix® Trifocal Intraocular lens, which is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL.Approval for the AcrySof® IQ PanOptix® Toric Trifocal Intraocular lens, which is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia and the reduction of residual refractive astigmatism, in adult patients in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL.
Source documents
Other decisions for Alcon Research, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K161794 · Decided Apr 14, 2017 · 288 days after receipt
Device type: Unit, Phacofragmentation (HQC) · Ophthalmology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.